Thursday, June 01, 2006
Is Fosamax the next Vioxx?
The lawyers are interested. The problem is osteonecrosis of the jaw, and class action status is being sought. Although fosamax is a major target, according to this systematic review in the Annals of Internal Medicine the major problem with biphosphonates and osteonecrosis is in patients receiving intravenous biphosphonates for myeloma and metastatic bone disease.
Subscribe to:
Post Comments (Atom)
1 comment:
That simply isn't true. Oral surgeons and dentists have been seeing patient after patient with jaw necrosis from Fosamax and other bisphosphonate drugs. For those who are interested in an unbiased perspective, we're posting news and commentary on the issue at our bone health blog, Got Bones?
Post a Comment